Immunosuppression for pancreas transplantation with an emphasis on antibody induction strategies: review and perspective. (January 2014)

• Record Type: Journal Article
• Authors: Stratta, Robert J; Farney, Alan C; Rogers, Jeffrey; Orlando, Giuseppe
• Is Part Of: Expert review of clinical immunology. Volume 10:Number 1(2014)
• Page Start: 117
• Page End: 132
• Publication Date: 2014-01
• Subjects: alemtuzumab -- antibody induction -- basiliximab -- calcineurin inhibitors -- diabetes mellitus -- mycophenolate -- rabbit antithymocyte globulin -- sirolimus -- steroid withdrawal -- tacrolimus; Clinical immunology -- Periodicals; 616.079
• DOI: 10.1586/1744666X.2014.853616
• Languages: English
• ISSNs: 1744-666X

Abstract

Abstract : A review of recent literature was performed to identify trends and evaluate outcomes with respect to immunosuppression in pancreas transplantation (PTX). In the past decade, the majority of PTXs were performed with depleting antibody induction, particularly in the setting of either calcineurin inhibitor minimization, corticosteroid withdrawal or both. Maintenance immunosuppression consisted of predominantly tacrolimus (TAC)/mycophenolatemofetil, TAC/mycophenolic acid or TAC/sirolimus with or without corticosteroids. Depending on PTX category, donor and recipient risk factors, case mix and immunosuppressive regimen, the 1-year incidence of acute rejection has decreased to 5–20%. Current 1-year rates of immunological pancreas graft loss range between 1.8 and 6%. Depleting antibody induction and either TAC/mycophenolatemofetil or TAC/sirolimus maintenance therapy with early steroid withdrawal have become the mainstay of immunosuppression in PTX. However, the development of non-nephrotoxic, nondiabetogenic, and nongastrointestinal toxic regimens is highly desirable to improve quality of life in all solid organ transplant recipients.